<SEC-DOCUMENT>0001437749-22-007691.txt : 20220330
<SEC-HEADER>0001437749-22-007691.hdr.sgml : 20220330
<ACCEPTANCE-DATETIME>20220330163339
ACCESSION NUMBER:		0001437749-22-007691
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220330
DATE AS OF CHANGE:		20220330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		22786964

	BUSINESS ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>dffn20220330_defa14a.htm
<DESCRIPTION>FORM DEFA14A
<TEXT>
<html><head>
	<title>dffn20220330_defa14a.htm</title>

	<!-- Generated by ThunderDome Portal - 3/30/2022 7:12:31 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SCHEDULE 14A INFORMATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Proxy Statement Pursuant to Section 14(a)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of the Securities Exchange Act of 1934 (Amendment No. ___)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed by the Registrant&nbsp;&#9746;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed by a Party other than the Registrant&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box:</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:7.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Preliminary Proxy Statement</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:7.7%;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt;">Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:7.7%;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt;">Definitive Proxy Statement</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;">

		<tr>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:7.7%;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt;">&#9746;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt;">Definitive Additional Materials</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-size: 10pt; font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0pt;">Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dffn20220330_defa14aimg001.jpg" src="dffn20220330_defa14aimg001.jpg" style="width:275;height:85;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name of Registrant as Specified In Its Charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Not Applicable</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Payment of Filing Fee (Check all boxes that apply):</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:7.7%;">&#9746;</td>
			<td style="vertical-align:top;width:auto;">No fee required</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:7.7%;">&#9744;</td>
			<td style="vertical-align:top;width:auto;">Fee paid previously with preliminary materials</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.1%;">&nbsp;</td>
			<td style="vertical-align:top;width:7.7%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dffn20220330_defa14aimg002.jpg" src="dffn20220330_defa14aimg002.jpg" style="width:241;height:78;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">SUPPLEMENT TO DEFINITIVE PROXY STATEMENT<br>
FOR THE SPECIAL MEETING OF STOCKHOLDERS<br>
TO BE HELD APRIL 14, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This supplement, dated March 30, 2022 (this &#8220;<u>Supplement</u>&#8221;), amends and supplements the Definitive Proxy Statement of Diffusion Pharmaceuticals Inc. (the &#8220;<u>Company</u>&#8221;), dated March 28, 2022 (the &#8220;<u>Proxy Statement</u>&#8221;), and is being furnished to stockholders of the Company in connection with the solicitation of proxies on behalf of the Company&#8217;s board of directors (the &#8220;<u>Board of Directors</u>&#8221;) for the Company&#8217;s Special Meeting of Stockholders to be held on April 14, 2022 (the &#8220;<u>Special Meeting</u>&#8221;) or any adjournment or postponement thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>THE PROXY STATEMENT CONTAINS IMPORTANT INFORMATION AND THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Special Meeting has been called for the purpose of seeking approval by the Company&#8217;s stockholders of (1) an amendment to the Company&#8217;s certificate of incorporation, as amended (the &#8220;<u>Certificate of Incorporation</u>&#8221;), to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-2 and 1-for-50, at any time prior to December 31, 2022, the implementation and timing of which shall be subject to the discretion of our Board of Directors and (2) adjournment of the Special Meeting if there are insufficient votes to approve Proposal 1.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Supplement, which should be read in conjunction with the Proxy Statement, amends and supplements the Proxy Statement to provide the information below. Except as specifically supplemented or amended by the information contained in this Supplement, all information set forth in the Proxy Statement continues to apply and should be considered in voting your shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">--------------</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>The paragraph in the General Information About the Special Meeting and Voting section under the heading, </i>&#8220;<i>How will shares of the Series C Preferred Stock be counted for purposes of determining the presence of a quorum at the Special Meeting?</i>&#8221;<i> on page 7 of the Proxy Statement is hereby amended to read as follows:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>How will shares of the Series C Preferred Stock be counted for purposes of determining the presence of a quorum at the Special Meeting?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For purposes of determining the presence of a quorum at the Special Meeting, in accordance with applicable listing rules, the Company will not count the shares of our Series C Preferred Stock, and therefore the Series C Preferred Stock will have no effect on the quorum.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>The second paragraph in the General Information About the Special Meeting and Voting section under the heading, </i>&#8220;<i>How will the presence of a quorum at the Special Meeting be determined?</i>&#8221;<i> on page 7 of the Proxy Statement is hereby amended to read as follows:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Accordingly, the presence at the Special Meeting, virtually or by proxy, of the holders of at least 33.4% of the shares entitled to vote at the Special Meeting as of the Record Date will constitute a quorum for the transaction of business at the Special Meeting, provided that shares of our Series C Preferred Stock will not be counted for such purpose. Accordingly, the presence at the Special Meeting of holders of at least 34,046,151 shares will be required to achieve a quorum.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>The General Information About the Special Meeting and Voting section of the Proxy Statement is hereby amended and supplemented by adding the following to the end of page 9 thereof:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b>Following the conclusion of the Special Meeting and any adjournment or postponement thereof, will the holders of the Series C Preferred Stock be entitled to 80,000 votes per share (or any other </b>&#8220;<b>super voting</b>&#8221;<b> rights) on any other matters?</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">No. Pursuant to the terms thereof, the holders of the Series C Preferred Stock are entitled to vote exclusively on matters directly related to the Reverse Stock Split and have no voting rights with respect to any other matter, except as otherwise required by applicable law. Following the conclusion of the Special Meeting (including any adjournment or postponement thereof), the holders thereof will not be entitled to any &#8220;super voting&#8221; rights on any matter. Moreover, assuming the Reverse Stock Split is approved at the Special Meeting, the Company intends to exercise its right to mandatorily convert the Series C Preferred Stock into shares of common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>The first paragraph on page 14 of the Proxy Statement under the heading, </i>&#8220;<i>Our Series C Preferred Stock</i>&#8221;<i> is hereby amended to read as follows:</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Each share of Series C Preferred Stock (i) has a stated value of $0.50, (ii) is convertible into one (1) share of our common stock at a price of $0.50 per share, (iii) in accordance with applicable listing rules, will not be counted and will have no effect for purposes of determining the presence of a quorum at the Special Meeting, (iv) will be entitled to 80,000 votes on Proposals 1 and 2 at the Special Meeting, and (v) will be required to cast such votes &#8220;For&#8221; and &#8220;Against&#8221; each proposal in the same proportion as our common stockholders present and voting at the meeting, taken as a whole (i.e., on a &#8220;mirrored&#8221; basis). In other words, holders of the Series C Preferred Stock are only permitted to vote with the holders of our common stock on proposals related to the Reverse Stock Split and are required to vote their shares of Series C Preferred Stock in a manner that &#8220;mirrors&#8221; the proportions of &#8220;For&#8221; and &#8220;Against&#8221; votes cast by the holders of the Company&#8217;s common stock on the Amendment (excluding, for the avoidance of doubt, any shares of common stock that are not voted). The shares of Series C Preferred Stock are not redeemable at any time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">--------------</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">From and after the date of this Supplement, all references to the &#8220;Proxy Statement&#8221; are to the Proxy Statement as amended and supplemented hereby. All capitalized terms used and not otherwise defined in this Supplement have the meanings given to them in the Proxy Statement.</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>dffn20220330_defa14aimg001.jpg
<TEXT>
begin 644 dffn20220330_defa14aimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 1,# 2(  A$! Q$!_\0
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M%UDC<)RK Y!_ @5T=%%@"BBB@#RCXU8,_@]67(.KJ"#C!'''^16G\8K/0_\
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M/9';JK#*QMD9;@@'IS^9+L#T:X\6:+:>$O\ A)YKD+I1A$ZR$<L&/  _O$X
M]ZY6W\=^+]1M5U+3/A[/+IK9:)KC44CF<'N$(..O3GZUP6NI-_PS]X-F8/\
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MP37K-&F.@*]^M%%,!^J_##1-3UZ;6(KC4=/N;D8NOL-TT0G^N/?K_DUH>'O
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I126H%[PCX/TSP7H\FFZ5YWE23-,[RMN8L<#KCL *WZ**8!1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>dffn20220330_defa14aimg002.jpg
<TEXT>
begin 644 dffn20220330_defa14aimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. /$# 2(  A$! Q$!_\0
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MLK?>DC/3/N.F:R?C_!&-&T6XVCS5NF0-CG:5Z?I7/? 1B/%VI '@V8R/^!4
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M*^/W_(:T/_KWD_F*T?V??^/;7O\ KK%_Z":Z_P <_#BV\<W=E<3ZE-:&U1D
MC0,&R>^:L^ _ ,'@:.^2#4);O[6RL3(@7;@8[5L>2<E\?_\ D7=(_P"OP_\
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@M&J>F:79:-81V.GVT5M:QYV11K@#/)JY0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
